Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RAET1M (Retinoic acid early transcript 1M) is annotated as a human pseudogene, not a functional receptor or protein. Pseudogenes are segments of DNA that resemble functional genes but are generally non-coding and non-functional due to mutations or deletions. While some members of the retinoic acid early transcript (RAET1) family encode ligands for the NKG2D receptor and play roles in immune surveillance, there is no evidence that RAET1M encodes a functional protein or is involved in any biological or disease process[3]. It is not considered a therapeutic target or biomarker. The query refers to a gene that is not a receptor, not a therapeutic target, and is non-functional. The designation "RAET1M" is correctly spelled, but by all current scientific standards, it cannot be classified among functionally relevant molecular targets[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retinoic acid early transcript 1M (pseudogene) (RAET1M).